XAGE-1b cancer/testis antigen is a potential target for immunotherapy in prostate cancer

Urologia Internationalis

Volumn 94, Issue 3, 2015, Pages 354-362

  Xie, Chong ^a   Wang, Guomin ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Cancer testis antigen; Eukaryotic expression vector; Immunotherapy; Prostate cancer; XAGE 1b

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN XAGE 1B; GAMMA INTERFERON; INTERLEUKIN 6; RESTRICTION ENDONUCLEASE; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; TUMOR ANTIGEN; XAGE1A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY ASSAY; DENDRITIC CELL; DNA SEQUENCE; EXPRESSION VECTOR; FVB MOUSE; GENE AMPLIFICATION; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; MYC CAP CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; WESTERN BLOTTING; WILD TYPE; ANIMAL; CELL LINE; CYTOLOGY; GENE THERAPY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; PROSTATIC NEOPLASMS; TESTIS TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE; DENDRITIC CELLS; DNA, COMPLEMENTARY; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; MALE; MICE; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; TRANSFECTION;

EID: 84928420971     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000363333     Document Type: Article

References (25)

1. Caballero OL, Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-2021.
2. Sang M, Lian Y, Zhou X, Shan B: MAGE-A family: attractive targets for cancer immunotherapy. Vaccine 2011; 29: 8496-8500.
3. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625.
4. Meek DW, Marcar L: MAGE-A antigens as targets in tumour therapy. Cancer Lett 2012; 324: 126-132.
5. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, Knuth A, Chen YT, Old LJ: NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30.
6. Brinkmann U, Vasmatzis G, Lee B, Pastan I: Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999; 59: 1445-1448.
7. Liu XF, Helman LJ, Yeung C, Bera TK, Lee B, Pastan I: XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. Cancer Res 2000; 60: 4752-4755.
8. Koizumi F, Noguchi Y, Saika T, Nakagawa K, Sato S, Eldib AM, Nasu Y, Kumon H, Nakayama E: XAGE-1 mRNA expression in prostate cancer and antibody response in patients. Microbiol Immunol 2005; 49: 471-476.
9. Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, Yoshino T, Yamashita K, Tsunoda T, Aoe M, Shimizu N, Nakayama E: XAGE-1 expression in nonsmall cell lung cancer and antibody response in patients. Clin Cancer Res 2005; 11: 5496-5503.
10. Sato S, Noguchi Y, Ohara N, Uenaka A, Shimono M, Nakagawa K, Koizumi F, Ishida T, Yoshino T, Shiratori Y, Nakayama E: Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun 2007; 7: 5.
11. Stames CO: Coley's toxins in perspective. Nature 1992; 357: 11-12.
12. Scanlan MJ, Simpson AJ, Old LJ: The cancer/ testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1.
13. Shamseddine A, Farhat FS, Elias E, Khauli RB, Saleh A, Bulbul MA: High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study. Urol Int 2013; 90: 56-61.
14. Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH: Cancer/testis antigens and urological malignancies. Nat Rev Urol 2012; 9: 386-396.
15. Huang CJ, Chen RH, Vannelli T, Lee F, Ritter E, Ritter G, Old LJ, Batt CA: Expression and purification of the cancer antigen SSX2: a potential cancer vaccine. Protein Expr Purif 2007; 56: 212-219.
16. Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W: A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One 2012; 7:e48424.
17. Ko YH, Miyake H, Behnsawy HM, Cheon J, Fujisawa M: Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression. Urol Int 2014; 93: 146-151.
18. Shantha Kumara HM, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, Gnjatic S, Cekic V, Old LJ, Simpson AJ, Cordon-Cardo C, Whelan RL: MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immun 2012; 12: 16.
19. Palucka K, Banchereau J: Dendritic-cellbased therapeutic cancer vaccines. Immunity 2013; 39: 38-48.
20. Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL: Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005; 65: 11565-11571.
21. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS: Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57: 205-225.
22. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382-5386.
23. Placek K, Coffre M, Maiella S, Bianchi E, Rogge L: Genetic and epigenetic networks controlling T helper 1. cell differentiation. Immunology 2009; 127: 155-162.
24. Bromberg J, Wang TC: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79-80.
25. Piriou L, Chilmonczyk S, Genetet N, Albina E: Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 2000; 41: 289-297.